P

Inventor

KING-UNDERWOOD JOHN

GB41 patents
⚠️ This page may combine multiple inventors who share the name “KING-UNDERWOOD JOHN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

RESPIVERT LTD

29 patents
US9108950B2Aug 18, 2015

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors

RESPIVERT LTD38 citations96
US9624196B2Apr 18, 2017

Inhibitor of p38 MAP kinase

RESPIVERT LTD15 citations92
US9475796B2Oct 25, 2016

1-pyrazolyl-3-((4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors

RESPIVERT LTD12 citations92
US9447076B2Sep 20, 2016

Inhibitor of p38 map kinase

RESPIVERT LTD16 citations92
US8975285B2Mar 10, 2015

P38 MAP kinase inhibitors

RESPIVERT LTD26 citations92
US9249125B2Feb 2, 2016

Pyrazole derivatives as p38 MAP inhibitors

RESPIVERT LTD30 citations91
US9724347B2Aug 8, 2017

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors

RESPIVERT LTD5 citations84
US9242960B2Jan 26, 2016

P38MAP kinase inhibitors

RESPIVERT LTD6 citations83
US10266519B2Apr 23, 2019

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors

RESPIVERT LTD6 citations82
US9850231B2Dec 26, 2017

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors

RESPIVERT LTD5 citations82
US9701670B2Jul 11, 2017

Pyrazolyl-ureas as kinase inhibitors

RESPIVERT LTD10 citations80
US10238658B2Mar 26, 2019

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors

RESPIVERT LTD3 citations73
US9993478B2Jun 12, 2018

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors

RESPIVERT LTD2 citations73
US10294216B2May 21, 2019

Pyrazolyl ureas as kinase inhibitors

RESPIVERT LTD1 citations72
US10738032B2Aug 11, 2020

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-i-yl) ureas as P38 mapkinase inhibitors

RESPIVERT LTD3 citations71
US11634406B2Apr 25, 2023

Inhibitor of p38 MAP kinase

RESPIVERT LTD0 citations62
US9340545B2May 17, 2016

Quinazolin-4 (3H)—one derivatives used as P13 kinase inhibitors

RESPIVERT LTD1 citations62
US9321773B2Apr 26, 2016

Compounds

RESPIVERT LTD2 citations62
US11142515B2Oct 12, 2021

Pyrazolyl-ureas as kinase inhibitors

RESPIVERT LTD0 citations61
US9884845B2Feb 6, 2018

Pyrazolyl-ureas as kinase inhibitors

RESPIVERT LTD1 citations61
US10813932B2Oct 27, 2020

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors

RESPIVERT LTD0 citations52
US10815217B2Oct 27, 2020

Inhibitor of p38 MAP kinase

RESPIVERT LTD0 citations51
US10045980B2Aug 14, 2018

Inhibitor of p38 map kinase

RESPIVERT LTD0 citations51
US10028959B2Jul 24, 2018

Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors

RESPIVERT LTD0 citations51
US10000471B2Jun 19, 2018

Pyrazole P38 map kinase inhibitors

RESPIVERT LTD0 citations51
US9834560B2Dec 5, 2017

Compounds

RESPIVERT LTD1 citations51
US9771354B2Sep 26, 2017

Pyrazole p38 map kinase inhibitors

RESPIVERT LTD1 citations51
US9637494B2May 2, 2017

Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors

RESPIVERT LTD0 citations51
US10144721B2Dec 4, 2018

P38 MAP kinase inhibitors

RESPIVERT LTD0 citations50

ITO KAZUHIRO

6 patents

KING-UNDERWOOD JOHN

3 patents

FYFE MATTHEW COLIN THOR

1 patent

JAGUAHR THERAPEUTICS PTE LTD

1 patent

PULMOCIDE LTD

1 patent